Notizie e Video - BIOCARTIS - Inglese

BIOCARTIS GROUP NV (Euronext Brussels: BCART) PRESS RELEASE - REGULATED INFORMATION - 09 May 2024, 07:00 CEST Biocartis Group NV provides an update regarding the publication of its annual report and the annual meeting Mechelen, Belgium, 09 May 2024 – Biocartis Group NV (the " Company ") (Euronext Brussels: BCART), announces today that it has decided to postpone the publication of its 2023 Annual Report, in view of the ongoing preparation of the contemplated voluntary dissolution and...

BIOCARTIS GROUP NV (Euronext Brussels: BCART) PRESS RELEASE - REGULATED INFORMATION - 10 January 2024, 23:00 CET Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings) 1. Summary of notice BIOCARTIS GROUP NV received a transparency notification on January 5, 2024, showing that JPMorgan Chase & Co., with registered office at c/o CT Corporation, 1209 Orange Street, Wilmington, DE19801, USA, following the acquisition...

BIOCARTIS GROUP NV (Euronext Brussels: BCART) PRESS RELEASE - REGULATED INFORMATION - 10 January 2024, 23:00 CET Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings) 1. Summary of notice BIOCARTIS GROUP NV received a transparency notification on January 5, 2024, of which an amended version was received on January 8, 2024, showing that Invesco Ltd., with registered office at 1331, Spring Street NW, Suite 2500,...

PRESS RELEASE - 22 November 2023, 10:00 CET BIOCARTIS HOLDINGS INC. RECAPITALIZATION COMPLETED AND PRODUCT PORTFOLIO EXPANSION The recapitalization of Biocartis was completed last week, strengthening the balance sheet with a new investment of €40 million and a €132 million conversion of debt to equity. Product portfolio expansion with the launch of three breast cancer products: the Idylla™ PIK3CA-AKT1 Mutation Assay and, in collaboration with our partner APIS, the APIS Breast Cancer...

PRESS RELEASE - 13 November 2023, 07:00 CET Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual Meeting Mechelen, Belgium and Itasca (IL), United States, 13 November 2023 – Biocartis, an innovative molecular diagnostics company, announces today that it will host a free corporate workshop at the Annual Meeting of the ‘Association for Molecular Pathology’ (AMP), a leading molecular diagnostics conference, taking place between 14-18...

PRESS RELEASE REGULATED INFORMATION 31 October 2023, 15:30 CET ANNOUNCEMENT REGARDING ENFORCEMENT BY SECURED CREDITORS The Company’s Secured Creditors have enforced their security over the shares of the Biocartis operating subsidiaries Enforcement not expected to impact Biocartis's customers, suppliers, partners or employees Mechelen, Belgium, 31 October 2023 – Biocartis Group NV (the “ Company ”) (Euronext Brussels: BCART) announces that it has been informed by its Secured Creditors (as...

PRESS RELEASE 16 October 2023, 7:00 CEST Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio Mechelen, Belgium, 16 October 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company, announces the launch of the new Breast Cancer Portfolio during the Breast Cancer Awareness month: the Idylla™ PIK3CA-AKT1 Mutation Assay and, in collaboration with APIS Assay Technologies (‘APIS’), the APIS Breast Cancer...

PRESS RELEASE 12 October 2023, 7:00 CEST Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit Mechelen, Belgium, 12 October 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company and APIS Assay Technologies Ltd. (‘APIS’), a private UK based company specializing in molecular diagnostics, today announced the expansion of their partnership 1 to include the...

PRESS RELEASE: 28 August 202 3 , 7:00 AM CE S T Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leaders Mechelen, Belgium, 28 August 202 3 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), is pleased to announce the appointment of a global Medical Advisory Board (MAB) comprised on renowned and influential KOLs in diagnostics, pharma and hospitals to advise, inform and guide Biocartis’...

PRESS RELEASE: 2 4 August 202 3 , 0 7: 0 0 CEST BIOCARTIS ANNOUNCES 202 3 HALF-YEAR RESULTS ON 26 SEPTEMBER 202 3 Mechelen, Belgium , 2 4 August 202 3 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today that it will report its 2023 half-year results and provide further updates on the status of its reorganization and financing & recapitalization plans on 26 September 2023, which is later than the...

PRESS RELEASE - INSIDE INFORMATION/ REGULATED INFORMATION 18 July 202 3 , 7:00 AM CE S T Biocartis appoints George Cardoza as new C F O and Head of Service Delivery George Cardoza appointed as Biocartis’ new Chief Financial Officer and Head of Service Delivery . Announced operational reorganization and cost reduction program pro gressing according to plan . Mechelen, Belgium, 18 July 202 3 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company...

PRESS RELEASE - REGULATED INFORMATION 20 June 2023, 17:40 CEST Disclosure of transparency notification Mechelen , Belgium, 20 June 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down...

PRESS RELEASE REGULATED INFORMATION 8 June 2023, 7:00 CEST Disclosure of transparency notification Mechelen , Belgium, 8 June 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down...

PRESS RELEASE: REGULATED INFORMATION 12 May 2023, 17:40 CEST Results of the Annual Shareholders’ Meeting held on 12 May 202 3 Mechelen, Belgium, 12 May 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), held its annual shareholders' meeting today at its offices in Mechelen, Belgium. The shareholders approved all items on the agenda, with the exception of the agenda item regarding the approval of certain...

PRESS RELEASE : 9 May 2023, 07:00 CEST Biocartis and HiloProbe to Collaborate on Col ore ctal Cancer Test Mechelen, Belgium, 9 May 2023 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), and HiloProbe, a Umeå (Sweden) based biotechnology company focused on personalizing colorectal cancer diagnostics, today announce that they entered into a collaboration that will initially focus on the commercialization of...

PRESS RELEASE: REGULATED INFORMATION 28 April 2023, 17:40 CEST Disclosure of Outstanding Voting Securities Mechelen, Belgium , 28 April 2023 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that in the course of April 2023 a further portion of receivables due by the Company to Highbridge under the senior secured 'Facility Agreement' (as amended from time to time) ("First Lien Loan Agreement") concluded...

PRESS RELEASE: INSIDE INFORMATION/ REGULATED INFORMATION 11 April 2023, 22:00 CEST Biocartis appoints Roger Moody as new CEO Roger Moody to be a ppointed as new Chief Executive Officer and member of the Board of Directors Herman Verrelst , current Chief Executive Officer , will move into the position of Executive Chairman of the Board of Directors Addit ional extensive experience in the US diagnostic market while leveraging existing knowledge and relationships Mechelen, Belgium, 11 April 202 3 -...

PRESS RELEASE - REGULATED INFORMATION 3 March 2023, 17:40 CET Disclosure of transparency notification Mechelen, Belgium , 3 March 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down...

PRESS RELEASE 2 March 2023, 7:00 CET BIOCARTIS ANNOUNCES THE US FDA 510( k ) CLEARANCE FOR THE IDYLL A ™ MSI TEST Mechelen , Belgium, 2 March 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the U.S. Food and Drug Administration (FDA) 510(k) clearance 1 for its fully automated Idylla™ MSI Test. This 510(k) clearance reinforces Biocartis’ commitment to enable clinical molecular...

PRESS RELEASE - REGULATED INFORMATION 23 February 2023, 07:00 CET BIOCARTIS ANNOUNCES 2022 RESULTS AND 2023 OUTLOOK The Company will host a conference call with live webcast presentation today at 14:30 CET / 13:30 GMT (UK) / 08:30 EST (US) to discuss the full year 2022 results Mechelen, Belgium, 23 February 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces its operational highlights and...